Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.46 |
| ▸ | ATR | Q13535 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4775512 | 0.88 | PIK3CA (0.47) | MAPTPIK3CAMTORATRCYP2C9 | |
| SCHEMBL3958927 | 0.83 | MAP3K11 (0.52) | MAPTCYP2C9PIM1PIM3PIM2 | |
| SCHEMBL18256867 | 0.77 | TDO2 (0.46) | MAPTPIK3CAATRCYP2C9PIM1 | |
| SCHEMBL1310236 | 0.75 | PIK3CA (0.59) | PIK3CAMTORATRCYP2C9JAK2 | |
| SCHEMBL16835984 | 0.74 | PIK3CA (0.48) | MAPTPIK3CAMTORATRCYP2C9 | |
| SCHEMBL442575 | 0.73 | JAK2 (0.56) | MAPTPIK3CAMTORATRCYP2C9 | |
| SCHEMBL30619464 | 0.73 | JAK2 (0.56) | MAPTPIK3CAMTORATRCYP2C9 | |
| SCHEMBL4243835 | 0.73 | KDM4E (0.48) | PIK3CAMTORCYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL22576432 | 0.72 | CKS1B (0.42) | MAPTJAK2TDO2HPGDJAK3 | |
| SCHEMBL22734977 | 0.72 | HRH3 (0.42) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315492-B1 | USE OF SUBSTITUTED PYRAZOLES FOR THE TREATMENT OF ALLERGIES | ORTHO MCNEIL PHARM INC (US) | 2008-07-30 | — | — | EP | disclosed |
| US-7265102-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1309592-B9 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1309592-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050234102-A1 | Substituted pyrazoles | CAI HUI | 2005-10-20 | — | — | US | disclosed |
| US-6951851-B2 | Substituted pyrazoles | CAI HUI | 2005-10-04 | — | — | US | disclosed |
| US-6949540-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-6936603-B2 | Substituted pyrazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040044027-A1 | Substituted pyrazoles | CAI HUI (US) | 2004-03-04 | — | — | US | disclosed |
| US-20030229075-A1 | Substituted pyrazoles | CAI HUI (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030225063-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225062-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635633-B2 | Substituted pyrazoles | ORTHO-PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6579896-B2 | Immunology response; autoimmune disease | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-17 | — | — | US | disclosed |
| EP-1315492-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309592-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020040019-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020013-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014317-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225062-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
| US-20030229075-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
| US-20020040019-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
| US-20040044027-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
| US-20030225063-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPT 3021/4885PIK3CA 2869/4885MTOR 3596/4885 |
| US-20050234102-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPT 3187/4885PIK3CA 2404/4885MTOR 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.